Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified ...

First-in-Human Results Demonstrate Favorable Safety and Pharmacokinetics ProfileAI Aided Target Engagement Research Advancing Development of ...

The use of chronotherapy has received increased attention over the past few years. However, data have been lacking on whether the pharmacokinetics of metformin vary over the course of the day. A new ...

Cyclosporine (CsA) is characterized by a narrow therapeutic window and high interindividual pharmacokinetic variability, particularly in juvenile patients. The aims of this study were to build a ...

A comprehensive overview of pharmacokinetics principles can be found in Chapter 5 of the widely used therapeutics textbook Pharmacotherapy: A Pathophysiologic Approach, 6th edition. [1] In addition, ...

MagnetisMM-9: An open-label, multicenter, non-randomized phase 1/2 study of elranatamab in patients with relapsed/refractory multiple myeloma. Background: Treatment of relapsed/refractory (R/R) ...

BUFFALO, N.Y. — When you pop a prescription pill into your mouth, you trust it to address the issue it was meant to fix. But what really happens? How is your body processing the drugs and what happens ...

Irrespective of what therapeutic area or drug target a discovery program pursues, a common bottleneck that cannot be avoided is pharmacokinetics and safety. Thus, all drugs must enter the body, ...

Discovering and bringing a new drug to market typically takes 14 years and costs approximately $ 2 billion USD. Today, the competitive landscape throughout the drug development process requires ...

Discovering and bringing a new drug to market typically takes 14 years and costs approximately $ 2 billion USD. Today, the competitive landscape throughout the drug development process requires ...